Prior to the open on Friday, Novavax (NVAX) announced the delay of the 4th annual Investor and Analyst Meeting from next week to November 9. The move is a big hit to investors hoping that the vaccine company would quickly provide a path forward for the RSV F vaccine that failed Phase 3 results. The stock has bounced from a low of around $1.15 to end the week at $1.80. The decent rebound was due in part to some insider buys. Sure the original date of the analyst meeting only provided one month to update shareholders on the path forward for the RSV vaccine, but this push back at the last minute suggests that Novavax might be struggling to find an easy resolution. As well, the company will need to provide an update on the financials where the cash balance was $366 million to end Q2, but the quarterly net loss was $79 million. By the November 9 meeting, the cash balance has to be down around $250 million. At this point, the meeting delay is sure to eat away at the stock for the next month. The plan should be to research the vaccine potential and see if the stock retests the original lows. Disclosure: No position